Paradigm is a private molecular information corporation established to bring cutting-edge diagnostics to cancer patients and industry by providing information about the genomic makeup of the patient's cancer and potential therapies based on the specific characterization of the patient's tumor that can impact the patient's course of treatment. Paradigm's Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/16/16 | $7,000,000 | Series B |
Mesa Verde Venture Partners | undisclosed |
| 05/15/19 | $8,000,000 | Series B Extension |
BlueStone Venture Partners Gore Range Ventures Mesa Verde Venture Partners New Science Ventures OSF Healthcare Prairie Ventures Tech Coast Angels | undisclosed |
